Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia

This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (VAP) in adult participants .

Key Inclusion Criteria:

• Participant has received mechanical ventilation for > 48 hours
• Acute Physiology and Chronic Health Evaluation (APACHE) II score of 11-35
• Presence of a new or progressive infiltrate on chest x-ray
• Presence of clinical criteria consistent with VAP

Key Exclusion Criteria:

• History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics
• Known end stage renal disease or requirement for dialysis